Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Women with early-stage breast cancer do not benefit from lymph node removal

A new study shows that removing lymph nodes due to the presence of occult, or microscopic, cancer cells found in the sentinel lymph node - the one closest to the tumor -- has no impact on survival outcomes of women with early-stage breast cancer.

27 Jul 2011

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.

26 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

Cord Blood Bank of Arkansas opens at UAMS

Celebrating the grand opening of the Cord Blood Bank of Arkansas at the University of Arkansas for Medical Sciences (UAMS) today, Brian and Jennifer Odle told how the use of cord blood gave their 18-month-old daughter a new lease on life.

20 Jul 2011

Possible new drug targets for treating diffuse large B-cell lymphoma

Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.

20 Jul 2011

UNC receives $3M federal grant for AIDS research

Scientists at the University of North Carolina at Chapel Hill schools of medicine and pharmacy have been awarded a $3 million federal grant to develop and test a new generation of treatments aimed at preventing sexual transmission of HIV to uninfected individuals.

19 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Coal seam gas and cancer risk: Report

An Australian Senate committee has been looking into the impact of coal seam gas (CSG) mining on the Murray-Darling Basin that has moved to Dalby on Queensland's western Darling Downs today. The Senate Standing Committee on Rural Affairs and Transport is touring southern Queensland examining the environmental consequences of CSG mining on the Murray-Darling River system.

19 Jul 2011

Nano-patterned plastic to advance stem cell research

Scientists have developed a novel plastic surface which overcomes the difficulties associated with growing adult stem cells. Standard surfaces have proved limited for growing large amounts and retaining the stem cells' useful characteristics. This discovery could lead to the creation of stem cell therapies for re-growing bone and tissue, and also for conditions such as arthritis. The study was carried out by Glasgow and Southampton universities.

18 Jul 2011

Study: Bone marrow transplant offers new hope for patients with high-risk leukemia

Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients treated at St. Jude Children's Research Hospital, with patients who lacked genetically matched donors recording the most significant gains. The results are believed to be the best ever reported for leukemia patients who underwent bone marrow transplantation.

15 Jul 2011

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

13 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

Lab grown windpipe saves cancer patient

A team of doctors have replaced the cancer affected windpipe of a patient with an organ made in a lab. This is a medical breakthrough for regenerative medicine. The patient no longer has cancer and is expected to have a normal life expectancy, doctors said.

10 Jul 2011

Bone Marrow News and Research

Further Reading

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Women with early-stage breast cancer do not benefit from lymph node removal

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

AMAG enters definitive merger agreement with Allos Therapeutics

Cord Blood Bank of Arkansas opens at UAMS

Possible new drug targets for treating diffuse large B-cell lymphoma

UNC receives $3M federal grant for AIDS research

Thalidomide analog shows promise against sickle cell disease

Coal seam gas and cancer risk: Report

Nano-patterned plastic to advance stem cell research

Study: Bone marrow transplant offers new hope for patients with high-risk leukemia

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

NeoStem to acquire Amorcyte

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

Lab grown windpipe saves cancer patient

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News